I can not imagine TGA having a typo on that type of statement lasting too long. this is from the EUA FDA notice
Document Revision Information
Doc Rev. 8.0
09/2021
Added the following statement to the Procedural limitations section: The performance of this test was
established based on the evaluation of a limited number of clinical specimens
You would hope our new man ex Abbot would know a thing or 2 about/rumours of the opposition Roche device.
I can not imagine TGA having a typo on that type of statement...
-
- There are more pages in this discussion • 659 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $51.83M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 37500 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 617809 | 6 |
View Market Depth
| Last trade - 07.25am 17/07/2024 (20 minute delay) ? |
| ADO (ASX) Chart |
Day chart unavailable